Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer
Shunyou Wang,Jing Gao,Qun-Ying Lei,Nora Rozengurt,Colin Pritchard,Jing Jiao,George Thomas,Gang Li,Pradip Roy-Burman,Peter S. Nelson,Xin Liu,Hong Wu +11 more
Reads0
Chats0
TLDR
Global assessment of molecular changes caused by homozygous Pten deletion identified key genes known to be relevant to human prostate cancer, including those "signature" genes associated with human cancer metastasis.About:
This article is published in Cancer Cell.The article was published on 2003-09-01 and is currently open access. It has received 1070 citations till now. The article focuses on the topics: PCA3 & Chromoplexy.read more
Citations
More filters
Journal ArticleDOI
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
TL;DR: In light of the recent advances in understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, the exciting therapeutic opportunities for targeting this pathway to treat these diseases are discussed.
Journal ArticleDOI
Molecular determinants of resistance to antiandrogen therapy
Charlie D. Chen,Derek S. Welsbie,Chris Tran,Sung Hee Baek,Randy Chen,Robert L. Vessella,Michael G. Rosenfeld,Charles L. Sawyers +7 more
TL;DR: Using microarray-based profiling of isogenic prostate cancer xenograft models, it is found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy.
Journal ArticleDOI
Targeting the phosphoinositide 3-kinase pathway in cancer.
TL;DR: The potential of and challenges for the development of therapeutic agents that target this pathway in cancer are discussed and the potential and challenges in understanding of the PI3K pathway are highlighted.
Journal ArticleDOI
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
TL;DR: The therapeutic potential of drugs targeting PI3K–Akt signalling for the treatment of cancer is discussed and the advantages and drawbacks of different treatment strategies for targeting this pathway are focused on.
Journal ArticleDOI
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh,Yi Liu,Merritt Edlind,Nicholas T. Ingolia,Matthew R. Janes,Annie Sher,Evan Y. Shi,Craig R. Stumpf,Carly Christensen,Michael Bonham,Shunyou Wang,Pingda Ren,Michael C. Martin,Katti Jessen,Morris E. Feldman,Jonathan S. Weissman,Kevan M. Shokat,Christian Rommel,Davide Ruggero +18 more
TL;DR: A clinically relevant ATP site inhibitor of mTOR, INK128, is developed, which reprograms this gene expression signature with therapeutic benefit for prostate cancer metastasis, for which there is presently no cure.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Significance analysis of microarrays applied to the ionizing radiation response
TL;DR: A method that assigns a score to each gene on the basis of change in gene expression relative to the standard deviation of repeated measurements is described, suggesting that this repair pathway for UV-damaged DNA might play a previously unrecognized role in repairing DNA damaged by ionizing radiation.
Journal ArticleDOI
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van't Veer,Hongyue Dai,Marc J. van de Vijver,Yudong D. He,Augustinus A. M. Hart,Mao Mao,Hans Peterse,Karin van der Kooy,Matthew J. Marton,Anke T. Witteveen,George J. Schreiber,Ron M. Kerkhoven,Christopher J. Roberts,Peter S. Linsley,René Bernards,Stephen H. Friend +15 more
TL;DR: DNA microarray analysis on primary breast tumours of 117 young patients is used and supervised classification is applied to identify a gene expression signature strongly predictive of a short interval to distant metastases (‘poor prognosis’ signature) in patients without tumour cells in local lymph nodes at diagnosis, providing a strategy to select patients who would benefit from adjuvant therapy.
Journal ArticleDOI
The phosphatidylinositol 3-Kinase AKT pathway in human cancer.
Igor Vivanco,Charles L. Sawyers +1 more
TL;DR: Small-molecule therapeutics that block PI3K signalling might deal a severe blow to cancer cells by blocking many aspects of the tumour-cell phenotype.
Journal ArticleDOI
Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN
Vuk Stambolic,Vuk Stambolic,Akira Suzuki,Akira Suzuki,José Luis de la Pompa,José Luis de la Pompa,Christine Mirtsos,Christine Mirtsos,Takehiko Sasaki,Takehiko Sasaki,Jürgen Ruland,Jürgen Ruland,Josef M. Penninger,Josef M. Penninger,David P. Siderovski,David P. Siderovski,Tak W. Mak,Tak W. Mak +17 more
TL;DR: The results show that PTEN may exert its role as a tumor suppressor by negatively regulating the PI3'K/PKB/Akt signaling pathway.
Related Papers (5)
Integrative genomic profiling of human prostate cancer
Barry S. Taylor,Nikolaus Schultz,Haley Hieronymus,Anuradha Gopalan,Yonghong Xiao,Brett S. Carver,Vivek K. Arora,Poorvi Kaushik,Ethan Cerami,Boris Reva,Yevgeniy Antipin,Nicholas Mitsiades,Thomas Landers,Igor Dolgalev,John E. Major,Manda Wilson,Nicholas D. Socci,Alex E. Lash,Adriana Heguy,James A. Eastham,Howard I. Scher,Victor E. Reuter,Peter T. Scardino,Chris Sander,Charles L. Sawyers,Charles L. Sawyers,William L. Gerald +26 more